286 related articles for article (PubMed ID: 35794161)
1. PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway.
Wang F; Yang L; Xiao M; Zhang Z; Shen J; Anuchapreeda S; Tima S; Chiampanichayakul S; Xiao Z
Sci Rep; 2022 Jul; 12(1):11444. PubMed ID: 35794161
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Interaction Regulates BCL2, KI67, BAX, and CASP3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid Leukemia.
Soltani M; Vosoughi M; Ganjalikhani-Hakemi M; Shapoorian H; Beshkar P; Eskandari N; Ghezelbash B
Iran J Allergy Asthma Immunol; 2023 Oct; 22(5):495-503. PubMed ID: 38085150
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
4. The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line.
Taghiloo S; Norozi S; Asgarian-Omran H
Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):178-188. PubMed ID: 35490271
[TBL] [Abstract][Full Text] [Related]
5. Indirubin, an Active Component of Indigo Naturalis, Exhibits Inhibitory Effects on Leukemia Cells
Yao Y; Li X; Yang X; Mou H; Wei L
Anticancer Agents Med Chem; 2024; 24(9):718-727. PubMed ID: 38347773
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway.
Zhang R; Tang P; Wang F; Xing Y; Jiang Z; Chen S; Meng X; Liu L; Cao W; Zhao H; Ma P; Chen Y; An C; Sun L
J Cell Biochem; 2019 Mar; 120(3):4423-4432. PubMed ID: 30367526
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.
Liu Y; Chen Y; Liu Y; Li M; Zhang Y; Shi L; Yang L; Li T; Li Y; Jiang Z; Liu Y; Wang C; Wang S
J Transl Med; 2022 Dec; 20(1):612. PubMed ID: 36550462
[TBL] [Abstract][Full Text] [Related]
9. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway.
Cheng J; Li Y; Liu S; Jiang Y; Ma J; Wan L; Li Q; Pang T
FASEB J; 2019 Apr; 33(4):4755-4764. PubMed ID: 30592634
[TBL] [Abstract][Full Text] [Related]
10. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
11. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
[TBL] [Abstract][Full Text] [Related]
13. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
14. Effects of Fibronectin 1 on Cell Proliferation, Senescence and Apoptosis of Human Glioma Cells Through the PI3K/AKT Signaling Pathway.
Liao YX; Zhang ZP; Zhao J; Liu JP
Cell Physiol Biochem; 2018; 48(3):1382-1396. PubMed ID: 30048971
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
[TBL] [Abstract][Full Text] [Related]
16. Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.
Gao Y; Feng Y; Liu S; Zhang Y; Wang J; Qin T; Chen P; Li K
Cancer Med; 2023 Jul; 12(14):15337-15349. PubMed ID: 37350549
[TBL] [Abstract][Full Text] [Related]
17. miR-338-3p Plays a Significant Role in Casticin-Induced Suppression of Acute Myeloid Leukemia via Targeting PI3K/Akt Pathway.
Yu K; Wang J; Hou J; Zhang L; Liang H
Biomed Res Int; 2022; 2022():9214130. PubMed ID: 35765408
[TBL] [Abstract][Full Text] [Related]
18. Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway.
Zhang X; Yang L; Liu X; Nie Z; Liu M; Wang T; Lu Y; Pan Y; Zhan Y; Wang Z; Luo J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119607. PubMed ID: 37852323
[TBL] [Abstract][Full Text] [Related]
19. Circ_0009910 sponges miR-491-5p to promote acute myeloid leukemia progression through modulating B4GALT5 expression and PI3K/AKT signaling pathway.
Wu Y; Zhao B; Chen X; Geng X; Zhang Z
Int J Lab Hematol; 2022 Apr; 44(2):320-332. PubMed ID: 34709725
[TBL] [Abstract][Full Text] [Related]
20. HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells.
Amornsupak K; Thongchot S; Thinyakul C; Box C; Hedayat S; Thuwajit P; Eccles SA; Thuwajit C
BMC Cancer; 2022 May; 22(1):578. PubMed ID: 35610613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
